personalized, responsive service and to improve the site, we remember and store information about how you use
Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
The Medicine Maker
Welcome to the February issue. Upfront investigates antibiotic pollution in the supply chain, a “pharmtastic” voyage, and the impact of cannabis legalization on pharma. In our cover feature, we speak with Martin Van Trieste and Mark Paxton from Rx-360 about how to better protect patients through supply chain security. NextGen explores checkpoint inhibitors, and in business, George Chressanthis explains what Donald Trump’s policies may mean for pharma. We also sit down with Catherine Bollard, President of the International Society for Cellular Therapy (ISCT).